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Thirteen point mutations of human interleakin-6 at the C-terminus were constructed at the eDNA.level, Two degenerate oliBonucleotid¢ primers 
were used for PCR synthesis of two groups or point mutations at positions 182 and 1114. The mutated cDNAs were in vitro transcribed and transla. 
ted and subsequently assayed for biological activity in the B9 cell proliferation test. Our results confirm our fornter findinlls obtained with deletion 
mutants on the importance of the C.terminus of IL-6 for biological activity, In additiotl, we now present ~videnc¢ for the importance of an a.hdis 
at the C.tern'finus of IL-6 and the presence of the positive charlle at position 1112 for biololtical activity. 
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1, INTRODUCTION 
IL-6 is a multifunctional cytokine involved in the im- 
mune defense, hematopoiesis and acute-phase protein 
regulation and exerts its action via specific surface 
receptors on the various target cells [1-3]. In order to 
understand the interaction of IL-6 with its receptor, 
structure-function studies have been carried out. 
Brakenhoff et al. [4] first showed that the deletion of 28 
amino acids from the N-terminus of IL-6 did not in- 
fluence the biological activity. Recent results from our 
laboratory have shown that the three carboxy-terminal 
amino acids of human IL-6 are essential for its bioac- 
tivity [5,6]. From the binding pattern of several mono- 
clonal antibodies Brakenhoff et al. concluded the ex- 
istence of an epitope composed of closely spaced 
residues from both the amino- and carboxy-terminals 
of IL-6 [7]. 
After the C-terminus of IL-6 had been shown to be 
important for biological function by deletion studies, 
we now describe experiments, where point mutations 
have been introduced into the full-length IL-6-molecule 
at the positions 182 and 184 crucial for biological activi- 
ty [5,6]. 
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2. MATERIALS AND METHODS 
2, I. Chemicals 
L.[s~S1methionine (> 3-/ TBq/mmol), 6.[~Hlth~midine [';4 
GBq/mmol) and [¢~-=~SJdATP 07 TBq/mmol) were purchased rrona 
Amcrsham International (Amersham, UK). All enzymes were ob- 
tained from Boehringer (Mannheim, Germany) For DNA sequencing 
the T7 DNA polymerase kit of Pharmacia/LgB (Freiburg, Germarty) 
was used, Human [L-6-cDNA and recombinant human IL.6 [8.9] 
were a generous gift of Drs, T, Hirano and T, Kishimoto (Osaka, 
Japan)', recombinant human IL-6 had a specific activity ot' 6x  10 m 
U/rag protein (B9 cell proliferation assay), 
2,2. Construction of  lL.6 mutants 
IL-6 mutants were constructed using PCR techniques [IG], 
IL-6-cDNA in pGEM4 [8] was amplified by PeR using one primer at 
the 5'.end (5'-TTG TAC ATA TTG TCG TT.3' ) and two different 
primers at the 3'-end (5'.GGATCCTAAGCTTCTACATTTG. 
CXYtAAGAGCCCTCAGGCTGG-3' ; 5' - CCTAAGCTTCTAXYz - 
TTTGCCGAAGAGCCCTCAG-3'), As shown in Fig. 1 X_.X.Yt and 
XY~ represent degenerate positions of the primers, The obtained 
II.,-6-cDNAs lacked the 3'.non.coding region and contained the 
translational stop codon TAG. PCR was can'led oat using 10 ng of 
plasmid DNA and 200 ng of each primer (annealing, 42°C, 120 s; syn- 
thesis, 72°C, 180 s; denaturation, 94°C, 90 s; 35 cycles), PCR pro- 
ducts were digested with EcoR 1 and Hindlll and subsequently cloned 
into the transcription vector pGEM3. All constructs were verified by 
DNA sequencing, in two cases multiple point mutations were obtain. 
ed inadvertently, In these two cases restriction fragments containing 
one point mutation were cloned into the wild type IL-6-cDNA. The 
exchange of Trp-157 to Arg was performed using the gapped uplex 
DNA technique [11] with the site directed mutagenesis kit from 
Boehringer (Mannheim, Germany). The linearized plasmids were 
transcribed with T7 RNA polymerase and subsequently translated in
a cell-free system (rabbit reticulocyte lysate) in the presence of 
[35S]methionine [121, After SDS.PAGE of the cell-free synthesized 
polypeptides, bands corresponding to wild.type and mutated IL.6 
were excised from the polyacrylamide gel and their radioactivity was 
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Fil~. I, Schematic representation f PCR primers used for tile construction ofpoint mutations in human IL.6.cDNA. The possible amino =scitl cx- 
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2.3, B9 cell prolO'erution u.s'su), 
The It..6 assay was carried out with the lL.6.dcpendcnt murine 
plasmacytoma cell line Bg, kindly provided by L. Aarden (Amster- 
dam, The Netherlands) 1131, One td of the translation mixture and 
serial dilutions (1:2) were used in tl~e B9 cell proliferation assay. 
3. RESULTS AND DISCUSSION 
To  define the precise structural requirements for the 
biological function of  IL-6, it was desirable to have a 
series of point mutations introduced into the C-terminal 
part of human IL-6. In previous studies [5] we have us- 
ed the classical 'gapped duplex' method for site. 
directed mutagenesis of  IL .6-cDNA [11] to exchange 
tryptophan.157 by arginine. This method is not very 
suitable for the preparation of numerous point muta- 
tions, because it is t ime-consuming and requires the 
synthesis of a new oligonucleotide for each construct, 
Therefore, we designed a strategy involving the use of 
a degenerate oligonucleotide combined with PCR- 
technique for the construction of  a series of point- 
mutants.  We have shown in previous studies [5,6] that 
methionine-184 and arginine-182 are of  particular im- 
portance for the biological activity of  IL-6. Fig. 1 shows 
two PCR-primers for the synthesis of 11 possible IL-6 
point mutants. PCR-products were ligated into the 
transcription-vector pGEM3 and analyzed by DNA- 
sequencing. We obtained 10 of the potential 11 point 
mutat ions (Fig. 2). In addition, we detected two unex- 
pected double mutations at positions 145/182 and 
176/184. The occurrence of unexpected mutations 
might be connected to the use of the degenerate 
oligonucleotides in the PCR, since no such mutations 
were observed, when perfect-matching oligonucleotides 
were used as primers. 
The constructed IL-6-cDNA mutants were cell-free 
transcribed and translated into the corresponding 
polypeptides. The biological activity of the synthesized 
IL-6 mutants was measured in the B9 cell proliferation 
assay. The values obtained were normalized as detailed 
in section 2.2, It is of  no importance that the cell-free 
synthesized IL-6-polypeptides carry a signal peptide of 
28 amino acids, since IL-6 obtained after cell-free 
transcription/translation shows the same biological ac- 
tivity regardless of the presence of a signal peptide (data 
not shown). 
Fig, 3 shows a comparison of  the biological activities 
of  all single point mutations. It is evident hat the muta- 
tions beyond amino acid 182do not affect biological ac- 
tivity of  IL-6 (left) with the exception of the mutant, 
where serine-176 is exchanged by proline. The low 
biological activity of this mutant  (13070 of the control) 
may be explained by the helix-breaking property of the 
amino acid proline, An o¢-helical structure at the 
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Fig. 2. C-terminal portion of human IL-6 and point mutations in. 
troduced, Bold letters in the wild-type IL-6-sequences indicate posi- 
tions, where point mutations have been introduced, 
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carboxy-terminus of  IL-6 has been predicted on the 
base of its primary struciure [5]. 
All lL-6-species with ahered amino acids at positions 
182 and 184 exhibit biological activities of <45°;'0 of  
controls (middle and right paris of Fig, 3), Similar to 
the mutant 176 the helix-breaking amino acid proline at 
position 182 severely impairs the biological activity of 
IL-6. Thus, it can be concluded that an a-h~lical strut- 
lure at the C-terminus of IL-6 is essential for its 
biological activity. 
The exchange of the positively charged amino acid 
arginine by glutamic acid, which bears a negative 
charge, also abrogates biological activity. The positive 
charge at position 182 is likely to be essential for a func- 
tional IL.6-molecule, since the replacement of 
arginine-182 by the positively charged lysine results in a 
rather active IL-6-polypeptide (4501o of  controls). In 
spite of the fact that arginine and lysine carry a positive 
charge, their side chains differ, This may explain why 
an IL-6.polypeptide carrying a lysine at position 182 
does not reach full biological activity. Interestingly, the 
arginine residue is conserved in human, mouse and rat 
IL-6. 
The exchange of  the C-terminal methionine by 
asparagine, serine or arginine results in IL-6-molecules 
with biological activities around 20010 of controls. 
However, when threonine, which is the C-terminal 
amino acid. o f  murine and rat IL-6, is introduced at this 
position, a mutant IL-6 of higher biological acitivity is 
created. 
It is an intriguing question, whether the IL-6 
mutants, which are biologically inactive, still bind to 
the IL-6-receptor. Prel iminary data (not shown) using 
cross-linking techniques uggest hat an IL-6 molecule 
lacking the four C-terminal amino acids does not bind 
to its receptor. Accordingly, this mutant  does not show 
biological activity. 
U~lnit molecular modelling Ba~an [14] r~centl~, pro- 
po~ed a tertiary structure common for l lrowih hor- 
mone, prola~:tine, llranulocyte colony stimulalintt fac- 
tor (G-CSF), erytllropoeitln =tad IL-6, This slru¢lure is 
eharacteri;4ed by 4 helices forminil a bundle, The C- 
terminal c/.heli,x i~ b~lieved to establish rec~ptor-litland 
re¢oltnition [14] by exposure of hydrophil ic amino 
acids. In lhe case of  IL-6, serine.176 and argininc-182 
are proposed to be localized at the surface, From oar 
f indinls the involvement of  an of.helical structure at the 
C.terminus of  IL.6 as well as the presence of  a positive 
char lc  (arginine-182] are essential for bioloilical func- 
tion, We surliest thai the C-terminal or.helix of' IL-6 
together with the correctly positioned positive charlte 
fits to a ritlid tlroove of the IL-6 receptor. 
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